Your browser doesn't support javascript.
loading
Association of Glycemic Variability With Imaging Markers of Vascular Burden, ß-Amyloid, Brain Atrophy, and Cognitive Impairment.
Jang, Hyemin; Lee, Sungjoo; An, Sungsik; Park, Yuhyun; Kim, Soo-Jong; Cheon, Bo Kyoung; Kim, Ji Hyun; Kim, Hee Jin; Na, Duk L; Kim, Jun Pyo; Kim, Kyunga; Seo, Sang Won.
Afiliação
  • Jang H; From the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan Univers
  • Lee S; From the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan Univers
  • An S; From the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan Univers
  • Park Y; From the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan Univers
  • Kim SJ; From the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan Univers
  • Cheon BK; From the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan Univers
  • Kim JH; From the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan Univers
  • Kim HJ; From the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan Univers
  • Na DL; From the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan Univers
  • Kim JP; From the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan Univers
  • Kim K; From the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan Univers
  • Seo SW; From the Alzheimer's Disease Convergence Research Center (H.J., S.A., Y.P., S.-J.K., B.K.C., J.H.K., H.J.K., D.L.N., J.P.K., S.W.S.), Samsung Medical Center; Department of Digital Health (H.J., S.L., K.K., S.W.S.), Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan Univers
Neurology ; 102(1): e207806, 2024 Jan 09.
Article em En | MEDLINE | ID: mdl-38165363
ABSTRACT
BACKGROUND AND

OBJECTIVE:

We aimed to investigate the association between glycemic variability (GV) and neuroimaging markers of white matter hyperintensities (WMH), beta-amyloid (Aß), brain atrophy, and cognitive impairment.

METHODS:

This was a retrospective cohort study that included participants without dementia from a memory clinic. They all had Aß PET, brain MRI, and standardized neuropsychological tests and had fasting glucose (FG) levels tested more than twice during the study period. We defined GV as the intraindividual visit-to-visit variability in FG levels. Multivariable linear regression and logistic regression were used to identify whether GV was associated with the presence of severe WMH and Aß uptake with DM, mean FG levels, age, sex, hypertension, and presence of APOE4 allele as covariates. Mediation analyses were used to investigate the mediating effect of WMH and Aß uptake on the relationship between GV and brain atrophy and cognition.

RESULTS:

Among the 688 participants, the mean age was 72.2 years, and the proportion of female participants was 51.9%. Increase in GV was predictive of the presence of severe WMH (coefficient [95% CI] 1.032 [1.012-1.054]; p = 0.002) and increased Aß uptake (1.005 [1.001-1.008]; p = 0.007). Both WMH and increased Aß uptake partially mediated the relationship between GV and frontal-executive dysfunction (GV → WMH → frontal-executive; direct effect, -0.319 [-0.557 to -0.080]; indirect effect, -0.050 [-0.091 to -0.008]) and memory dysfunction (GV → Aß â†’ memory; direct effect, -0.182 [-0.338 to -0.026]; indirect effect, -0.067 [-0.119 to -0.015]), respectively. In addition, increased Aß uptake completely mediated the relationship between GV and hippocampal volume (indirect effect, -1.091 [-2.078 to -0.103]) and partially mediated the relationship between GV and parietal thickness (direct effect, -0.00101 [-0.00185 to -0.00016]; indirect effect, -0.00016 [-0.00032 to -0.000002]).

DISCUSSION:

Our findings suggest that increased GV is related to vascular and Alzheimer risk factors and neurodegenerative markers, which in turn leads to subsequent cognitive impairment. Furthermore, GV can be considered a potentially modifiable risk factor for dementia prevention.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças do Sistema Nervoso Central / Doenças Neurodegenerativas / Demência / Leucoaraiose / Disfunção Cognitiva Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças do Sistema Nervoso Central / Doenças Neurodegenerativas / Demência / Leucoaraiose / Disfunção Cognitiva Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article